Biotechnology Reagents & Kits Market Size to Hit US$ 1.14 Trillion by 2030

The global Biotechnology Reagents & Kits market size is expected to hit around US$ 1.14 Trillion by 2030 from valued at US$ 437.28 billion in 2020 with a CAGR of 26.5% during forecast period 2021 to 2030.

Growth Factors

Key factors driving the market include the introduction of novel and advanced products, a rise in investments in the biotechnology sector, and increasing demand for synthetic biology.

Increasing research and development expenditure for life sciences and biotechnology research is expected to drive the market significantly in the coming years. Over the past few decades, the biotechnology sector has witnessed a paradigm shift toward new treatments & drugs, biologically controlled production processes, genetically modified foods, biologically based computing, and new materials, thereby propelling the market growth.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38329

Advancements in molecular diagnostic techniques, such as droplet digital PCR, NGS, and genome-wide sequencing with respect to accuracy, reproducibility, and timeline, have influenced the adoption of biotechnology reagents & kits in the market. The advent of long-read sequencing has made sequencing of longer strands of DNA possible by only reading single DNA molecules, in turn, driving the market growth.

Report Highlights

The detection kits segment dominated the market in 2020 with a revenue share of over 32%. This can be attributed to the widespread utilization of detection kits at various end-use settings, such as healthcare, industrial processing, food, and agriculture. With the growing need to curb the COVID-19 virus, the production of detection kits has increased over the past few months.

For instance, in May 2021, the Defence Research and Development Organisation’slaboratory, the Defence Institute of Physiology and Allied Sciences (DIPAS), introduced an antibody-dependent kit DIPCOVAN DIPAS-VDx SARS-CoV-2 IgG antibody Microwell ELISA for sero-surveillance. This kit can recognize both Spikes and Nucleocapsid (S&N) protein of coronavirus with 97% sensitivity and 99% specificity. The detection kit is manufactured in collaboration with Vanguard Diagnostics Private Limited.

Cell culture technology dominated the market with a revenue share of more than 34% in 2020 and is followed by Polymerase Chain Reaction (PCR) technology. Increasing demand for cell culture reagents by the research community is driving the segment growth. The comprehensive portfolio of cell culture media and reagents owned by companies has supplemented the market growth.

PCR is one of the key technologies used for the detection and analysis of specific gene sequences. Currently available real-time PCR assays offer high specificity and sensitivity, and are, thereby, considered the go-to methods for various genomic studies. Currently, the PCR technique is considered the most accurate, for the detection of COVID-19, leading to a significant increase in the adoption of PCR testing kits and reagents.

The RNA segment accounted for the largest revenue share of over 39% owing to the increasing research on transcriptomics. Research on extracellular RNA for clinical diagnosis has increased over the past five years. Companies and universities are entering into the field for the development of RNA-based therapeutics by the virtue of transcriptomic technologies. Key industry participants are constantly introducing new products to drive the market. For instance, in March 2021, PromegaCorp. launchedXpressAmp Direct amplification reagent.

It enables RNA extraction-free sample preparation, which is automation-friendly. Such advancements are expected to drive market growth.DNA testing has significant application in newborn genetic screening, identity diagnostics & forensics, pharmacogenomics diagnostic testing, and drug metabolism, which is expected to drive the segment growth. Increasing demand for DNA diagnostics technology is the major driver of this segment.

The virus segment accounted for the highest revenue share of over 41% in 2020, which is closely followed by the bacteria segment. The dominance of the segment can be attributed to the increasing application of viruses in gene therapy and vaccinology. Increasing R&D to support the use of recombinant viral vectors in vaccine development further drives the segment.

Furthermore, the outbreak of SARS-COV-2 infection acts as a driving factor for the market as there is an increase in demand for viral reagents, which is propelling the segment growth. The rising number of SARS-CoV-2 cases has fueled the demand for tests and reagents for testing as well as research purposes, thereby driving developments in the segment. 

The on-site purposes segment led the market in 2020 with a revenue share of over 65%. The rising utilization of Point-of-Care (POC) testing has primarily driven the segment growth. Efficient and timely POC testing based on the availability of POC reagents has supplemented the segment growth.

On-site testing applications in the food and beverage industry also aided the market expansion. It includes microbiological on-site testing and enzymatic on-site testing. Microbiological on-site testing is used in the detection of viruses, bacteria, and molds in food. Enzymatic on-site testing is used in the measurement of constituents, such as acid or alcohol and sugar in foods. This test is essential when analyzing beverage and dairy products.

The healthcare sector dominated the market in 2020 with a revenue share of over 60%. The segment will retain the leading position throughout the forecast years owing to the ongoing clinical trials and research & development activities for clinical diagnostics. Moreover, a shift in preference toward molecular diagnostics and personalized medicine has increased mergers and collaborations for developing novel technology.

This has subsequently driven the demand for various advanced products in the healthcare sector. For instance, in March 2021, Roche and GenMark diagnostics entered into a merger agreement to introduce innovative technology to test a wide range of pathogens with one patient specimen. GenMark’sePlex platform provides quick and effective results.

North America dominated the global market with a revenue share of more than 47% in 2020. The presence of key players actively developing technologically advanced novel products coupled with the introduction of several new products by emerging start-ups has majorly contributed to the dominance of the region.

Key Players

• Thermo Fisher Scientific
• QIAGEN
• New England Biolabs
• Illumina, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Promega Corp.
• Takara Bio, Inc.
• LGC Ltd.
• Toyobo Co. Ltd.

Market Segmentation

• Kit Type Outlook
  • Purification Kits
  • Amplification Kits
  • Detection Kits
  • Isolation Kits
  • Others
• Technology Outlook 
  • LAMP Technology
  • PCR
  • Cell Culture
  • Sequencing
  • Chromatography
  • Electrophoresis
  • Flow Cytometry
  • Other Technologies
• Tested Parameters Outlook 
  • DNA
  • RNA
  • Enzymes
  • Proteins
  • Others
• Micro-Organisms Outlook
  • Bacteria
  • Virus
  • Fungi
  • Parasites
• Purpose Outlook 
  • On-Site
  • Laboratory
• End-use Outlook 
  • Healthcare
  • Food & Agriculture
  • Natural Resources & Environment
  • Industrial Processing
  • Others
• Regional Outlook
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa (MEA)

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38329

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333